Non-Hodgkin’s Lymphoma And Chronic Lymphocytic Leukemia – Emerging Therapies – Venclexta Launch Tracking (US) Wave 2

Venclexta (Wave 2) is the second in a multiwave series designed to track physician perception, uptake, and competitive environment regarding the newly launched chronic lymphocytic leukemia (CLL) drug, Venclexta (Roche/AbbVie’s venetoclax). Launch Tracking Venclexta measures the impact of this novel agent on the relapsed/refractory CLL with del(17p) therapy market following launch, based on a blend of quantitative and qualitative primary research with U.S. hematologist-oncologists. This content evaluates physicians’ current awareness and perception of Venclexta relative to other currently available therapies for relapsed/refractory CLL, current and anticipated use of Venclexta, and promotional activity of Venclexta.

Questions answered:

  • What are the awareness of and familiarity with Venclexta among hematologist-oncologists?
  • What are the perceived clinical advantages and disadvantages of Venclexta compared with other marketed agents used for treating relapsed/refractory CLL?
  • To what extent is Venclexta currently being used by surveyed hematologist-oncologists? Where does Venclexta fit in the treatment algorithm? What reasons do nonprescribers give for not having prescribed Venclexta?
  • What promotional messages are being employed by Roche/AbbVie?

Scope:

Market covered: United States.

Primary research: 75 hematologist-oncologists; qualitative interviews with 10 respondents.

Indication coverage: Relapsed/refractory CLL.

Table of contents

  • Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Emerging Therapies - Venclexta Launch Tracking (US) Wave 2
    • Key Findings
      • Benchmarking Venclexta Launch Success vs. the Competition
        • Venclexta Experiences A Low Level of Use Among Physicians Compared with Other Benchmarking Agents
      • Prescriber and Nonprescriber Profiles
        • Who Is the Venclexta Prescriber?
        • Differences Between Venclexta Prescriber and Nonprescriber Profiles
      • Venclexta Awareness and Perceptions
        • Unaided and Aided Awareness of Venclexta
          • Unaided Awareness of Drugs for Treatment of CLL
          • Awareness of Venclexta
          • Physician Perception of Venclexta's Approved Indications
          • Physician Perception of Venclexta's Administration
          • Awareness of Venclexta's Price
          • Perceived Price of Venclexta
          • Physician Quotes on the Perceived Advantages and Disadvantages of Venclexta
        • Familiarity with Venclexta
          • Mean Level of Familiarity with Venclexta
        • Sources of Familiarity with Venclexta
          • Venclexta Sources of Familiarity
          • Other Sources of Familiarity with Venclexta
        • Initial Reaction to and Interest in Venclexta
          • Venclexta Product Profile
          • Physicians Indicate a Moderate to High Level of Interest in Venclexta
          • Initial Reaction to Venclexta
          • Interest in Venclexta
          • Physician Quotes on Initial Reaction to and Interest in Venclexta
        • Impressions of Venclexta
          • Awareness of Venclexta Profile
          • Venclexta Attributes of Which Hematologist-Oncologists Were Unaware
          • Other Venclexta Attributes of Which Hematologist-Oncologists Were Unaware
          • Uniqueness of Venclexta
          • Perceived Advantages of Venclexta
          • Perceived Disadvantages of Venclexta
          • Value of Venclexta Characteristics
          • Mean Value of Venclexta Characteristics
          • Risk/Benefit Perception of Venclexta
          • Physician Quotes on Impressions of Venclexta
        • Prescriber and Nonprescriber Profiles
        • Venclexta Trial and Use
          • Willingness to Prescribe Venclexta
            • Physician Willingness to Prescribe Venclexta to R/R CLL Patients with Del(17p)
            • Impact of Select Attributes on Physician Willingness to Prescribe Venclexta
            • Mean Value of Impact of Select Attributes on Physician Willingness to Prescribe Venclexta
            • Impact of Venclexta's Accelerated Approval Based on ORR Data of Physician Likelihood to Prescribe
            • Physician Quotes on Willingness to Prescribe Venclexta
          • Number of Patients Currently Receiving Venclexta
            • Venclexta Prescription Rate
            • Patient Share in the Second-Line CLL Del(17p) Setting Now and in Five Months' Time
            • Rituxan-Based Regimens Used in Second-Line Del(17p) Setting Now and in Five Months' Time
            • Patient Share in the Third-Line CLL Del(17p) Setting Now and in Five Months' Time
            • Rituxan-Based Regimens Used in Third-Line Del(17p) Setting Now and in Five Months' Time
            • Other Regimens Used in Third-Line Del(17p) Setting Now and in Five Months' Time
            • Venclexta Discontinuation Rate Among Prescribers
            • Reasons for Discontinuing Venclexta Treatment
            • Treatment Selection Following Venclexta Discontinuation
            • Rituxan-Based Regimens Used Following Venclexta Discontinuation
            • Other Treatments Used Following Venclexta Discontinuation
            • Venclexta Prescribing Practices
            • Treatment Prior to Switching to Venclexta
            • Reasons for Prescribing Venclexta
            • Primary Obstacles to Prescribing Venclexta to More R/R CLL Patients with Del(17p)
            • Patient Inquiries Regarding Venclexta in Past Month
            • Mean Number of Patient Inquiries Regarding Venclexta in Past Month
            • Hematologist-Oncologists' Action Based on Specific Patient Inquiries
            • Physician Quotes on Current Use of Venclexta
          • Reasons for Not Yet Prescribing Venclexta
            • Key Reasons for Not Yet Prescribing Venclexta
            • Other Reasons for Not Yet Prescribing Venclexta
            • Physician Quotes on Reasons for Not Prescribing Venclexta
          • Anticipated Venclexta Use
            • Anticipated Venclexta Use Among Nonprescribers
            • Percentage of Second-Line and Third-Line CLL Patients Eligible for Venclexta
            • Potential Displacement of Existing Treatments by Venclexta
            • Rituxan-Based Therapies Likely to Be Replaced by Venclexta
            • Physician Quotes on Anticipated Venclexta Use
          • Venclexta Performance on Key Attributes
            • Overall Level of Satisfaction with Venclexta for Treatment of R/R CLL with Del(17p)
            • Level of Satisfaction with Venclexta on Key Metrics
            • Mean Levels of Satisfaction with Venclexta on Key Attributes
            • Physician Rating of Venclexta on Key Attributes
            • Performance of Venclexta on Key Attributes
            • Physician Quotes on Venclexta Performance on Key Attributes
        • Effectiveness of Face-to-Face Detailing for Venclexta
          • Venclexta Sales Representative Frequency and Reach
            • Last Time of Contact with a Venclexta Representative
            • Physician Quotes on Venclexta Sales Representative Visit Frequency and Reach
          • Satisfaction with Venclexta Sales Representative
            • Sales Representative Performance on Key Attributes
            • Physician Quotes on Satisfaction with Venclexta Sales Representatives
          • Venclexta Message Recall
            • Topics Discussed by Sales Representatives
            • Positioning of Venclexta Against Other Products
        • Appendix
          • Abbreviations

        launch Related Market Assessment Reports